MA54157A - Dérivés de spiro-sulfonamide en tant qu'inhibiteurs de la protéine de la leucémie myéloïde -1 (mcl-1) - Google Patents
Dérivés de spiro-sulfonamide en tant qu'inhibiteurs de la protéine de la leucémie myéloïde -1 (mcl-1)Info
- Publication number
- MA54157A MA54157A MA054157A MA54157A MA54157A MA 54157 A MA54157 A MA 54157A MA 054157 A MA054157 A MA 054157A MA 54157 A MA54157 A MA 54157A MA 54157 A MA54157 A MA 54157A
- Authority
- MA
- Morocco
- Prior art keywords
- mcl
- spiro
- myeloid leukemia
- protein inhibitors
- sulfonamide derivatives
- Prior art date
Links
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title 1
- 208000025113 myeloid leukemia Diseases 0.000 title 1
- 229940121649 protein inhibitor Drugs 0.000 title 1
- 239000012268 protein inhibitor Substances 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862758202P | 2018-11-09 | 2018-11-09 | |
| US201962907451P | 2019-09-27 | 2019-09-27 | |
| US201962909635P | 2019-10-02 | 2019-10-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54157A true MA54157A (fr) | 2021-09-15 |
Family
ID=68808529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054157A MA54157A (fr) | 2018-11-09 | 2019-11-08 | Dérivés de spiro-sulfonamide en tant qu'inhibiteurs de la protéine de la leucémie myéloïde -1 (mcl-1) |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11130769B2 (fr) |
| EP (1) | EP3877390A1 (fr) |
| JP (1) | JP2022506973A (fr) |
| KR (1) | KR20210089662A (fr) |
| CN (1) | CN113166173A (fr) |
| AU (1) | AU2019374907A1 (fr) |
| BR (1) | BR112021008796A2 (fr) |
| CA (1) | CA3118919A1 (fr) |
| IL (1) | IL283078A (fr) |
| MA (1) | MA54157A (fr) |
| MX (1) | MX2021005463A (fr) |
| WO (1) | WO2020097577A1 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112118845B (zh) | 2018-05-14 | 2023-06-13 | 吉利德科学公司 | Mcl-1抑制剂 |
| BR112022000251A2 (pt) * | 2019-07-09 | 2022-05-17 | Janssen Pharmaceutica Nv | Derivados macrocíclicos de espirociclo como inibidores de mcl-1 |
| TW202115095A (zh) * | 2019-08-16 | 2021-04-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| EP4013761A1 (fr) * | 2019-08-16 | 2022-06-22 | Inflazome Limited | Dérivés de sulfonylurée macrocycliques utiles en tant qu'inhibiteurs de nlrp3 |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| PT4065567T (pt) | 2019-11-26 | 2024-11-08 | Gilead Sciences Inc | Processos e intermediários para a preparação de inibidores de mcl1 |
| KR20230024287A (ko) * | 2020-05-13 | 2023-02-20 | 프렐루드 테라퓨틱스, 인코포레이티드 | 골수 세포 백혈병-1 (mcl-1) 단백질의 억제제로서의 스피로-술폰아미드 유도체 |
| CN115698023A (zh) * | 2020-06-10 | 2023-02-03 | 詹森药业有限公司 | 作为mcl-1抑制剂的大环2-氨基-3-氟-丁-3-烯酰胺 |
| JP7659630B2 (ja) | 2020-11-19 | 2025-04-09 | ギリアード サイエンシーズ， インコーポレイテッド | 大環状ｍｃｌ１阻害剤を調製するための方法及び中間体 |
| CN116670141A (zh) | 2020-12-17 | 2023-08-29 | 詹森药业有限公司 | 作为mcl-1抑制剂的大环支化3-氟-丁-3-烯酰胺 |
| JP2024516641A (ja) | 2021-04-26 | 2024-04-16 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１阻害剤としての大環状２－アリルテトラヒドロフラン |
| JP7673255B2 (ja) | 2021-06-11 | 2025-05-08 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ |
| TWI910028B (zh) | 2021-06-11 | 2025-12-21 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗癌劑之組合 |
| CN115677616B (zh) * | 2021-11-03 | 2024-10-18 | 中国药科大学 | 大环磺酰胺类化合物及其制备方法和医药用途 |
| JP2024544570A (ja) | 2021-11-16 | 2024-12-03 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１阻害剤としての大環状２－アミノ－ブト－３－エナミド |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3657744A (en) | 1970-05-08 | 1972-04-25 | Univ Minnesota | Method for fixing prosthetic implants in a living body |
| US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5061273A (en) | 1989-06-01 | 1991-10-29 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US5350395A (en) | 1986-04-15 | 1994-09-27 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US5040548A (en) | 1989-06-01 | 1991-08-20 | Yock Paul G | Angioplasty mehtod |
| US4748982A (en) | 1987-01-06 | 1988-06-07 | Advanced Cardiovascular Systems, Inc. | Reinforced balloon dilatation catheter with slitted exchange sleeve and method |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| CA1322628C (fr) | 1988-10-04 | 1993-10-05 | Richard A. Schatz | Greffon vasculaire intraluminal |
| US6344053B1 (en) | 1993-12-22 | 2002-02-05 | Medtronic Ave, Inc. | Endovascular support device and method |
| US5674278A (en) | 1989-08-24 | 1997-10-07 | Arterial Vascular Engineering, Inc. | Endovascular support device |
| US5292331A (en) | 1989-08-24 | 1994-03-08 | Applied Vascular Engineering, Inc. | Endovascular support device |
| ME03780B (fr) * | 2013-01-15 | 2021-04-20 | Incyte Holdings Corp | Dérivés de thiazolecarboxamide et pyridinecarboxamide et leur utilisation comme inhibiteurs des kinases pim |
| JO3474B1 (ar) * | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| WO2017147410A1 (fr) | 2016-02-25 | 2017-08-31 | Amgen Inc. | Composés inhibant la protéine mcl-1 |
| CN106565706B (zh) * | 2016-10-27 | 2018-05-01 | 广东东阳光药业有限公司 | 一种磺酰胺衍生物及其在药学中的应用 |
| JP6453507B2 (ja) * | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
-
2019
- 2019-11-08 US US16/679,105 patent/US11130769B2/en not_active Expired - Fee Related
- 2019-11-08 MA MA054157A patent/MA54157A/fr unknown
- 2019-11-08 EP EP19816994.8A patent/EP3877390A1/fr not_active Withdrawn
- 2019-11-08 WO PCT/US2019/060638 patent/WO2020097577A1/fr not_active Ceased
- 2019-11-08 AU AU2019374907A patent/AU2019374907A1/en not_active Abandoned
- 2019-11-08 JP JP2021525143A patent/JP2022506973A/ja active Pending
- 2019-11-08 BR BR112021008796-6A patent/BR112021008796A2/pt not_active Application Discontinuation
- 2019-11-08 MX MX2021005463A patent/MX2021005463A/es unknown
- 2019-11-08 KR KR1020217013796A patent/KR20210089662A/ko not_active Withdrawn
- 2019-11-08 CN CN201980073752.1A patent/CN113166173A/zh active Pending
- 2019-11-08 CA CA3118919A patent/CA3118919A1/fr active Pending
-
2021
- 2021-05-09 IL IL283078A patent/IL283078A/en unknown
- 2021-08-17 US US17/404,808 patent/US20230010358A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA3118919A1 (fr) | 2020-05-14 |
| MX2021005463A (es) | 2021-06-18 |
| US20230010358A1 (en) | 2023-01-12 |
| EP3877390A1 (fr) | 2021-09-15 |
| WO2020097577A1 (fr) | 2020-05-14 |
| US11130769B2 (en) | 2021-09-28 |
| IL283078A (en) | 2021-06-30 |
| BR112021008796A2 (pt) | 2021-08-03 |
| US20200148705A1 (en) | 2020-05-14 |
| AU2019374907A1 (en) | 2021-06-03 |
| KR20210089662A (ko) | 2021-07-16 |
| CN113166173A (zh) | 2021-07-23 |
| JP2022506973A (ja) | 2022-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3768671A4 (fr) | Dérivés d'imidazolidine-2-one substitués en tant qu'inhibiteurs de prmt5 | |
| MA54452A (fr) | Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a | |
| MA51610A (fr) | Dérivés d'imidazole fusionnés utilisés en tant qu'inhibiteurs d'il-17 | |
| MA49013A (fr) | Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 | |
| MA52486A (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
| EP3853220A4 (fr) | Dérivés de quinazoline en tant qu'agents antitumoraux | |
| EP3784665A4 (fr) | Dérivés de pyridazine en tant qu'agents de dégradation de smarca2/4 | |
| MA47125A (fr) | Dérivés de pyrazole en tant qu'inhibiteurs de malt1 | |
| EP3941525A4 (fr) | Dérivés de benzodiazépine en tant qu'inhibiteurs de rsv | |
| EP3687543A4 (fr) | Agents pharmaceutiques en combinaison en tant qu'inhibiteurs de rsv | |
| MA45189A (fr) | Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 | |
| MA46339A (fr) | Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30 | |
| MA47123A (fr) | Dérivés de benzooxazole en tant qu'mmunomodulateurs | |
| MA45153A (fr) | Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux | |
| MA48987A (fr) | Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA48943A (fr) | Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA51998A (fr) | Nouveaux polymorphes de sel de calcium en tant qu'agents anti-inflammatoires, immunomodulateurs et anti-prolifératifs | |
| EP3416964A4 (fr) | Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk | |
| MA44498A (fr) | Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
| MA46981A (fr) | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine | |
| EP3953331A4 (fr) | Pyrazolesulfonamides en tant qu'agents antitumoraux | |
| MA44502A (fr) | Dérivés d'indole substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA50439A (fr) | Nouveaux dérivés de pyrazolo-pyrrolo-pyrimidine-dione utilisés en tant qu'inhibiteurs de p2x3 | |
| EP4043450A4 (fr) | Dérivés 2h-benzopyrane utilisables en tant qu'inhibiteurs de crac | |
| MA41341A (fr) | Dérivés indole utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue |